https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Monopar_Therapeutics_Inc.Monopar Therapeutics Inc. - Revizia istoricului2026-04-06T02:27:28ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Monopar_Therapeutics_Inc.&diff=430741&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Monopar Therapeutics Inc. listata cu simbolul US.MNPR ==Descriere companie== Monopar Therapeutics Inc. (https://www.monopartx.com/) is a clinical-stage biopharmaceutical company. The Company is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe...2024-09-18T18:13:18Z<p>Pagină nouă: Pagina dedicata companiei Monopar Therapeutics Inc. listata cu simbolul US.MNPR ==Descriere companie== Monopar Therapeutics Inc. (https://www.monopartx.com/) is a clinical-stage biopharmaceutical company. The Company is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Monopar Therapeutics Inc. listata cu simbolul US.MNPR<br />
<br />
==Descriere companie==<br />
Monopar Therapeutics Inc. (https://www.monopartx.com/) is a clinical-stage biopharmaceutical company. The Company is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.MNPR" /><br />
<br />
==Ultimele stiri despre Monopar Therapeutics Inc. (US.MNPR)==<br />
<dynamicpagelist><br />
category=US.MNPR<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.MNPR]][[Categorie:Stiri despre companii]]</div>Admin